# A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas

> **NCT07217171** · PHASE1 · RECRUITING · sponsor: **EvolveImmune United, Inc** · enrollment: 160 (estimated)

## Conditions studied

- Bladder Cancer
- Squamous Cell Carcinoma of the Lung
- Esophageal Squamous Cell Carcinoma
- Tongue Squamous Cell Carcinoma
- Cutaneous Squamous Cell Cancer
- Penile Squamous Cell Carcinoma
- Anal Squamous Cell Carcinoma
- Vulvar Squamous Cell Carcinoma
- Cervical Squamous Cell Carcinoma
- Vaginal Squamous Cell Carcinoma
- Urethral Squamous Cell Carcinoma

## Interventions

- **DRUG:** EVOLVE104
- **DRUG:** EVOLVE104

## Key facts

- **NCT ID:** NCT07217171
- **Lead sponsor:** EvolveImmune United, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-13
- **Primary completion:** 2029-01-29
- **Final completion:** 2031-01-29
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07217171

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07217171, "A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07217171. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*